Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Mepenzolate is an antagonist of muscarinic (M) acetylcholine receptors (Kis = 0.68 and 2.6 nM for human M2 and M3 receptors, respectively).1 It has antispasmodic activity in the gastrointestinal tract of anesthetized cats and dogs when administered at a dose of 0.5 mg/kg.2 Mepenzolate decreases airspace enlargement induced by elastase or cigarette smoke and reduces respiratory dysfunction in a mouse model of chronic obstructive pulmonary disease (COPD).3 It also reduces oxidative stress, decreases the expression of IL-1β, IL-6, and TNF-α, and increases the expression of TGF-β1, IGF-1, and VEGF in a diabetic wound healing mouse model.4
WARNING This product is not for human or veterinary use.
1. Synthesis and biological comparison of enantiomers of mepenzolate bromide, a muscarinic receptor antagonist with bronchodilatory and anti-
2. The comparative antispasmodic activity of N-
3. Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease. Nat. Commun. 4:2686, (2013).
4. Mepenzolate bromide promotes diabetic wound healing by modulating inflammation and oxidative stress. Am. J. Transl. Res. 8(6), 2738-2747 (2016).